Skip to main content

Intra-abdominal Infections

7
Pipeline Programs
6
Companies
6
Clinical Trials
3
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
0
1
3
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
3100%
+ 5 programs with unclassified modality

On Market (3)

Approved therapies currently available

Pfizer
FLAGYL I.V. RTU IN PLASTIC CONTAINERApproved
metronidazole
Pfizer
injection1980
Pfizer
FLAGYL ERApproved
metronidazole
Pfizer
oral1997
Pfizer
FLAGYLApproved
metronidazole
Pfizer
oral1963

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
3 programs
1
1
MetronidazolePhase 3Small Molecule1 trial
TigecyclineN/ASmall Molecule1 trial
TigecyclineN/ASmall Molecule1 trial
Active Trials
NCT00827541Completed115Est. Dec 2010
NCT01789905Completed116Est. Jun 2017
NCT01473836Completed38Est. Oct 2012
Sandoz
SandozAustria - Kundl
1 program
1
LYS228Phase 21 trial
Active Trials
NCT03354754Terminated3Est. Sep 2018
MSD
MSDIreland - Ballydine
1 program
1
Relebactam 250 mgPhase 2
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
1
Relebactam 250 mgPhase 21 trial
Active Trials
NCT01506271Completed351Est. Aug 2014
Novartis
NovartisBASEL, Switzerland
1 program
LYS228PHASE_2
Qilu Pharmaceutical
Qilu PharmaceuticalChina - Jinan
1 program
Meropenem and PralurbactamPHASE_31 trial
Active Trials
NCT06633718Not Yet Recruiting786Est. May 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Qilu PharmaceuticalMeropenem and Pralurbactam
PfizerMetronidazole
SandozLYS228
Sharp TherapeuticsRelebactam 250 mg
PfizerTigecycline
PfizerTigecycline

Clinical Trials (6)

Total enrollment: 1,409 patients across 6 trials

NCT06633718Qilu PharmaceuticalMeropenem and Pralurbactam

Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in CIAI

Start: Oct 2024Est. completion: May 2027786 patients
Phase 3Not Yet Recruiting
NCT01473836PfizerMetronidazole

A Phase 3 Study Of Intravenous Metronidazole For Intrabdominal Infection

Start: Nov 2011Est. completion: Oct 201238 patients
Phase 3Completed
NCT03354754SandozLYS228

LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Intra-abdominal Infection (cIAI)

Start: May 2018Est. completion: Sep 20183 patients
Phase 2Terminated
NCT01506271Sharp TherapeuticsRelebactam 250 mg

Study of the Safety, Tolerability, and Efficacy of Relebactam (MK-7655) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone to Treat Complicated Intra-Abdominal Infection [cIAI] (MK-7655-004)

Start: Jun 2012Est. completion: Aug 2014351 patients
Phase 2Completed
NCT01789905PfizerTigecycline

Tygacil Drug Use Investigation

Start: Apr 2013Est. completion: Jun 2017116 patients
N/ACompleted
NCT00827541PfizerTigecycline

Post-Authorization Study Evaluating Safety Of Tigecycline

Start: Aug 2008Est. completion: Dec 2010115 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.